A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation

Abstract

The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human

Clinical factors affecting engraftment and transfusion needs in SCT: a single-center retrospective analysis

“…10 Transfusion considerations vary in the pre, peri and post transplant settings. 11 The work reported here demonstrates that contemporary SCT remains associated with significant periods of thrombocytopenia and with need for transfusion support with both red cells and platelets, even when using currently recommended thresholds of hemoglobin of 8 g/dL and platelets of 10 Â 10 9 /L to trigger transfusion. We restricted our analysis to first transplants because second transplants have of themselves been associated with increased frequency and duration of transfusion need.…”

Analysis of Abo Group Discrepancies in a Tertiary Care Centre South India

“…Blood group chimerism is an intrinsic characteristic of ABO non-identical HPC transplantation. The erythrocyte chimerism [11] helps in using the blood products with donor ABO typing or not. In our case, patient showed full-donor chimera indicating successful engraftment.…”

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

“…Only leukocyte-depleted erythrocyte and platelet components should be given to decrease the risk of HLA-associated alloimmunization and reduce the risk of CMV transmission. 314 Both autologous and allogeneic stem cell recipients are at risk for transfusion-associated GVHD. Gamma irradiation (at least 25 Gy) is the only reliable method to prevent transfusion-associated GVHD.…”